← Leaderboards
Marla J Keller
Mount Sinai School Of Medicine Of Nyu
$31,813,832
Attributed
$46,029,302
Total exposure
28
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.6M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$58,420,879 · 29
By mechanism
UL1$43,147,452 · 12
U19$5,683,029 · 4
UM1$4,368,000 · 1
U01$2,336,605 · 1
R33$1,449,892 · 1
M01$854,901 · 8
Top collaborators
- Harry Shamoon18 shared
- Betsy C. Herold5 shared
- Mimi Y. Kim2 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Donald P Waller$987,837
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchEnvironmentSafetyVaginaProgramsInnovationWomanCellsPharmaceutical PreparationsInfectionClinical TrialsCommunitiesFemaleCytokineTenofovirHiv InfectionsAntileukoproteasePreventMicrobicideGenital SystemPathway InteractionsMediator Of Activation ProteinCervicalDesign
Grant awards (57)
Einstein-Montefiore Clinical and Translational Science Award Hub$4,368,000
UM1 · FY2023 · TR · contact PI
Clinical and Translational Science Award$4,274,173
UL1 · FY2022 · TR · contact PI
Clinical and Translational Science Award$4,274,173
UL1 · FY2021 · TR · contact PI
Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 hospitalized pa$4,325,153
UL1 · FY2020 · TR · contact PI
Clinical and Translational Science Award$4,274,173
UL1 · FY2020 · TR
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients$1,003,424
UL1 · FY2020 · TR
Clinical and Translational Science Award$4,274,173
UL1 · FY2019 · TR
Clinical and Translational Science Award$2,880,704
UL1 · FY2018 · TR
Clinical and Translational Science Award$1,393,469
UL1 · FY2018 · TR
Clinical and Translational Science Award$4,663,559
UL1 · FY2017 · TR
Core-004$790,950
UL1 · FY2017 · TR
Core-003$695,859
UL1 · FY2017 · TR
Core-008$516,005
UL1 · FY2017 · TR
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$498,512
U19 · FY2017 · AI · contact PI
Core-001$467,348
UL1 · FY2017 · TR
Core-002$431,007
UL1 · FY2017 · TR
Core-009$390,882
UL1 · FY2017 · TR
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$322,595
U19 · FY2017 · AI · contact PI
Core-006$309,790
UL1 · FY2017 · TR
Core-005$247,228
UL1 · FY2017 · TR
Core-010$167,000
UL1 · FY2017 · TR
Core-007$40,364
UL1 · FY2017 · TR
Clinical and Translational Science Award$4,636,811
UL1 · FY2016 · TR
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$819,806
U19 · FY2016 · AI · contact PI
Clinical and Translational Science Award$3,091,207
UL1 · FY2015 · TR
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$638,902
U19 · FY2015 · AI · contact PI
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$248,506
U19 · FY2015 · AI · contact PI
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$889,629
U19 · FY2014 · AI · contact PI
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota$895,694
U19 · FY2013 · AI · contact PI
Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF$908,327
U19 · FY2012 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$470,988
R33 · FY2012 · AI
Novel Mucosal Models Predictive of Microbicide Safety$480,904
R33 · FY2011 · AI
Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF$461,058
U19 · FY2011 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$498,000
R33 · FY2010 · AI
Microbicide Effects on Efficacy, Safety, Innate Immunity$410,188
U01 · FY2010 · AI · contact PI
Safety of Non-Medicated Intravaginal Rings for Microbicide Delivery$124,500
R34 · FY2010 · AI · contact PI
Microbicide Effects on Efficacy, Safety, Innate Immunity$442,288
U01 · FY2009 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$228,250
R21 · FY2009 · AI
Microbicide Effects on Efficacy, Safety, Innate Immunity$429,277
U01 · FY2008 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$228,250
R21 · FY2008 · AI
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE$179,311
M01 · FY2008 · RR · contact PI
Microbicide Effects on Efficacy, Safety, Innate Immunity$207,376
U01 · FY2007 · AI · contact PI
Microbicide Effects on Efficacy, Safety, Innate Immunity$200,113
U01 · FY2007 · AI · contact PI
THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1$41,017
M01 · FY2007 · RR · contact PI
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE$34,041
M01 · FY2007 · RR · contact PI
Microbicide Effects on Efficacy, Safety, Innate Immunity$431,839
U01 · FY2006 · AI · contact PI
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV$53,780
M01 · FY2006 · RR · contact PI
TO EVALUATE THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1$49,034
M01 · FY2006 · RR · contact PI
EFFECTS OF HIV ON BONE MASS IN THE ELDERLY$45,874
M01 · FY2006 · RR · contact PI
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATORS$26,892
M01 · FY2006 · RR · contact PI
Microbicide Effects on Efficacy, Safety, Innate Immunity$215,524
U01 · FY2005 · AI
EFFECTS OF HIV ON BONE MASS IN THE ELDERLY$162,265
M01 · FY2005 · RR
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATO$112,155
M01 · FY2005 · RR
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV$71,587
M01 · FY2005 · RR
TO EVALUATE THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1 U...$55,555
M01 · FY2004 · RR
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV$23,390
M01 · FY2004 · RR
In Vivo Antiviral &Inflammatory Effects of Microbicides$0
U19 · FY2002 · HD